Immunocore(IMCR)
OXFORDSHIRE, United Kingdom
BiotechnologyFocus: T Cell Receptor Fragment Therapies
Immunocore is a life sciences company focused on T Cell Receptor Fragment Therapies.
OncologyInfectious Diseases
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (1)
Pipeline & Clinical Trials
Tebentafusp
Uveal MelanomaClinical Trials (1)
NCT04960891A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
N/AIMC-P115C
PRAME PositiveClinical Trials (1)
NCT07156136Study of IMC-P115C in Advanced PRAME-Positive Cancers
Phase 1IMC-I109V Single Ascending Dose
Hepatitis B, ChronicClinical Trials (1)
NCT05867056Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
Phase 1IMCgp100
Malignant MelanomaClinical Trials (1)
NCT01211262Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Phase 1Tebentafusp
Malignant MelanomaClinical Trials (1)
NCT02535078Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Phase 1/2IMC-R117C
CancerClinical Trials (1)
NCT06840119Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Phase 1/2IMC-C103C
Select Advanced Solid TumorsClinical Trials (1)
NCT03973333Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Phase 1/2IMCgp100
Uveal MelanomaClinical Trials (1)
NCT02570308A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Phase 1/2Brenetafusp
Select Advanced Solid TumorsClinical Trials (1)
NCT04262466Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Phase 1/2IMCnyeso
Select Advanced Solid TumorsClinical Trials (1)
NCT03515551Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Phase 1/2IMCgp100
Malignant MelanomaClinical Trials (1)
NCT02889861IMCgp100-401 Rollover Study
Phase 2Tebentafusp
Uveal MelanomaClinical Trials (1)
NCT06070012Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Phase 2Tebentafusp
Melanoma (Skin)Clinical Trials (1)
NCT05315258Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Phase 2Tebentafusp
Metastatic Uveal MelanomaClinical Trials (1)
NCT06627244Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Phase 2IMCgp100
Uveal MelanomaClinical Trials (1)
NCT03070392Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Phase 2Tebentafusp
Uveal MelanomaClinical Trials (1)
NCT06246149Adjuvant Tebentafusp in High Risk Ocular Melanoma
Phase 3Tebentafusp
Advanced MelanomaClinical Trials (1)
NCT05549297Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3Brenetafusp
Advanced MelanomaClinical Trials (1)
NCT06112314IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 1 approved product, 18 clinical trials
Top TAs: Oncology, Infectious Diseases
Publications: 25 in PubMed
SEC Filings: 2 available
Portfolio Health
Peak1 (100%)
1 total products
Financials (FY2025)
Revenue
$249M43%
R&D Spend
$164M(66%)60%
Net Income
-$55MCash
$456M